Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis : Episode 10
BTK Inhibitors' Rationale and Potential Role in Multiple Sclerosis Treatment
Heidi Crayton, MD, discusses the rationale for investigating Bruton tyrosine kinase inhibitors (BTKis) as a treatment for patients with multiple sclerosis and the current stage of development for evobrutinib, tolebrutinib, and other BTKis.
EP: 1.Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis
EP: 2.Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression
EP: 3.Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis
EP: 4.Examining Key Unmet Needs in Multiple Sclerosis
EP: 5.Patient Satisfaction: Opportunity for Better Multiple Sclerosis Therapies
EP: 6.MS Treatment Guidelines: Expert Insights on Updates and Decision-Making
EP: 7.Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment
EP: 8.Examining Challenges with Drug Switching and Step Therapy in MS Treatment
EP: 9.Typical Payer Coverage Criteria for Multiple Sclerosis Therapies
Now Viewing
EP: 10.BTK Inhibitors' Rationale and Potential Role in Multiple Sclerosis Treatment
EP: 11.Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis
EP: 12.Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies
EP: 13.Multiple Sclerosis: Looking Toward the Future
Video content above is prompted by the following questions:
- What was the rationale for the investigation of Bruton tyrosine kinase inhibitors (BTKis) for use as treatment in patients with multiple sclerosis (MS)?
- What is the stage in development for evobrutinib, tolebrutinib and other BTKis?
- How might these therapies fit into treatment algorithms for different types of MS?
- How do payers see these therapies being integrated into treatment algorithms?
Related Videos
Related Content
Real-World Discontinuations of Ocrelizumab in MS Comparable to Pivotal Trials
January 9th 2025Article
Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in pivotal clinical trials among patients with different types of multiple sclerosis (MS).
Read More
